## 3 Results
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Authors** & \begin{tabular}{c} **Number and Study Types** \\ **Included in the Analysis** \\ \end{tabular} & \begin{tabular}{c} **Number of Patients** \\ **Included in the Research** \\ \end{tabular} & \begin{tabular}{c} **Type of Drug** \\ **Therapy Used** \\ \end{tabular} \\ \hline Madrid \& [PERSON] (2009) [51] & 1 P-CCS; 3 RE & 1561 & Bisphosphonate \\ \hline [PERSON] et al. (2009) [52] & 15 RCT & 10,707 & Bisphosphonate \\ \hline [PERSON] et al. (2018) [53] & Unclear & 4106 & \begin{tabular}{c} Antiresportive (including \\ denosumab) \\ \end{tabular} \\ \hline [PERSON] et al. (2010) [54] & Unclear & 39,124 & Bisphosphonate \\ \hline [PERSON] et al. (2020) [55] & 3 PR; 10 RE; 1 CS & 2100 & \
\begin{tabular}{c} Antiresportive (including \\ denosumab) \\ \end{tabular} \\ \hline [PERSON] et al. (2009) [56] & 72 CS; 33 CR & 656 & Bisphosphonate \\ \hline [PERSON] et al. (2021) [57] & 2 RCT; 5 CSS & 7755 & Antiresportive \\ \hline [PERSON] et al. (2016) [58] & 1 RCT & 49 & Bisphosphonate \\ \hline [PERSON] et al. (2021a) [59] & 9 RE; 8 CS; 10 CR & 206 &
\begin{tabular}{c} Bisphosphonate and \\ anti-TNF inhibitors \\ \end{tabular} \\ \hline [PERSON] et al. (2021b) [60] & 3 PR; 2 RE; 2 CS; 6 CR & 37 & Bisphosphonate \\ \hline [PERSON] et al. (2021c) [61] & 1 RCT; 7 CS; 20 CR & 36 & Antiangiogenic \\ \hline [PERSON] et al. (2019) [62] & 1 RCT; 5 PR; 4 RE; 3 CS & 188 & Antiresportive \\ \hline [PERSON] et al. 2006 [63] & Unclear & 368 & Bisphosphonate \\ \hline [PERSON] et al. (2021) [64] & 1 RE; 1 CS; 5 CR & 29 & Bisphosphonate \\ \hline \hline \end{tabular}
\end{table} 
Table 3: _Cont._  
\begin{table}
\begin{tabular}{c c} \hline \hline \multicolumn{2}{c}{**Non-Interventional Reviews**} \\ \hline
**Author** & **Result** \\ \hline \multirow{6}{*}{[PERSON] et al. (2017)[40]} & The mean age of MRONJ osteoporosis patients in our study was 69.7 \(\pm\) 5.2 years. The mandible was the most common site (394, 70.6%), followed by maxilla (152 case, 27.2%) and then in both of them (only 12 cases, 2.2%). The ratio of mandible to maxilla and both jaws involvement was 2.4:1. There was variability in the duration of BPs therapy, which ranged from 2 weeks to 93 months, with a mean duration of 51.9 \(\pm\) 18 months. Extraction was the most frequently reported preceding event (244 patients, 48.5%). \\ \hline \multirow{6}{*}{[PERSON] et al. (2021)[42]} & The data acquired from the moderate/high risk of bias studies suggested that 2–3 g of amoxicillinfilm daily, either alone or in combination with clavulanate, for 6–7 days is the most commonly used antibiotic treatment to minimize risk of MRONJ in patients requiring a dental extraction, which could provide reduction of MRONJ risk. \\ \hline \multirow{6}{*}{[PERSON] et al. (2017)[43]} & All eight of the selected studies found that CTX levels were not predictive of the development of BRONJ. In conclusion, this systematic review indicates that the CTX test has no predictive value in determining the risk of osteonecrosis in patients taking bisphosphonates. \\ \hline \multirow{6}{*}{[PERSON] et al. (2020)[44]} & Although no cases of osteonecrosis were identified, all studies had weaknesses such as a limited sample size or the absence of risk factors for the development of osteonecrosis. However, it is believed that patients with secondary osteoporosis who use bisphosphonates continuously should be followed up during adulthood, since bone turnover decreases over the years. \\ \cline{1-1}  & \\ \cline{